When TV doctors call you to make an appointment

When TV doctors call you to make an appointment

Actor Patrick Dempsey is helping patients get over the pressure of scheduling an appointment

Pro ad report 2017: Ad revenue plunged for print-first publishers

Pro ad report 2017: Ad revenue plunged for print-first publishers

The 2017 numbers aren't kind to print-first publishers. Is this a blip in print's fortunes or the start of a long-predicted decline?

Dr. Reddy's Laboratories CEO of developed markets Alok Sonig makes Wall Street listen

Dr. Reddy's Laboratories CEO of developed markets Alok Sonig makes Wall Street listen

Alok Sonig, chief executive officer of developed markets at Dr. Reddy's Laboratories, articulates the benefits of generics.

AbbVie veteran Mark Stenhouse joins Cologuard as president

AbbVie veteran Mark Stenhouse joins Cologuard as president

He spent more than 30 years at the pharmaceutical company.

ICER said a $14,000 drug should be a fraction of the cost. Why its makers listened.

ICER said a $14,000 drug should be a fraction of the cost. Why its makers listened.

In an unusual twist, the makers of cholesterol drug Praluent are re-pricing the treatment to align with the nonprofit's recommendation. Is industry warming to ICER?

ePharma: Novo Nordisk's lessons from a diabetes education campaign

ePharma: Novo Nordisk's lessons from a diabetes education campaign

Why the drugmaker's partnership with a YouTube star is still getting hits.

Forum: Should outcomes-based pricing be the blueprint for all specialty drug launches?

Forum: Should outcomes-based pricing be the blueprint for all specialty drug launches?

As drugmakers continue to experiment with novel pricing models for expensive new specialty drugs, MM&M asked a trio of industry insiders whether outcomes-based pricing should become standard.

DTC pharma ad spending slipped 4.6% in 2017: Kantar

DTC pharma ad spending slipped 4.6% in 2017: Kantar

Direct-to-consumer drug marketing spend dropped most heavily in the magazine and digital categories.

Infographic | What Makes Patients Tick?

Infographic | What Makes Patients Tick?

Now more than ever, patients aren't shy about sharing their wants and needs. Here, 8,000 patients from three generations in the U.S., U.K., Germany, and France weigh in on everything from brand loyalty to the factors that drive their decision-making-processes to the reasons they switch treatments.

Teva rebrands in North America amid global restructuring

Teva rebrands in North America amid global restructuring

The pharmaceutical company is undergoing a global restructuring as it relaunches its brand in the U.S. and Canada.

Virta Health CEO Sami Inkinen on changing patient behavior: 'We're cutting down trees in the wrong forest'

Virta Health CEO Sami Inkinen on changing patient behavior: 'We're cutting down trees in the wrong forest'

Seven questions for the Virta Health chief executive and cofounder of Trulia.

Why Facebook's algorithm change may benefit patient influencers

Why Facebook's algorithm change may benefit patient influencers

A WEGO Health white paper examined how the change could affect patient influencers.

Dohmen Life Science acquired by Water Street Healthcare, JLL Partners

Dohmen Life Science acquired by Water Street Healthcare, JLL Partners

Dohmen will continue to operate under its brand and retain its leadership team.

Havas Formula named PR AOR for Colorado Center for Reproductive Medicine

Havas Formula named PR AOR for Colorado Center for Reproductive Medicine

The agency began working with the national reproductive center this month.

Infographic | Highlighting top healthcare trends

Infographic | Highlighting top healthcare trends

There was so much bigger-picture coverage of pharma and healthcare in 2017 - pricing, Affordable Care Act reform and repeal - that it was easy to lose sight of everything else. PwC's Health Research Institute has used its annual look-ahead report to spotlight a handful of undercover trends.

Payers: High-deductible health plans don't drive positive consumer behavior

Payers: High-deductible health plans don't drive positive consumer behavior

As the evidence mounts that high-deductibles don't cause patients to shop or save for healthcare, payers are taking note.

Latest set of Humira commercials debuts to mixed patient response

Latest set of Humira commercials debuts to mixed patient response

Critics said the initial spots unnecessarily blamed IBD sufferers.

Five things for pharma marketers to know: Tuesday, February 6, 2018

Five things for pharma marketers to know: Tuesday, February 6, 2018

Allergan Q4 earnings beat estimates; Mars publishes research policies; Conway takes control of White House opioid agenda.

Five things for pharma marketers to know: Monday, February 5

Five things for pharma marketers to know: Monday, February 5

Opdivo hits key goal in late-stage trial; Philippines government sues Sanofi over anti-dengue vaccine; hospitals reach capacity amid record flu season.

Merck hands off to Jim Kelly for Super Bowl, World Cancer Day combo campaign

Merck hands off to Jim Kelly for Super Bowl, World Cancer Day combo campaign

This year, the Super Bowl and World Cancer Day fall on the same date.

Easterseals Southern California campaign aims to change perceptions of disabilities

Easterseals Southern California campaign aims to change perceptions of disabilities

The nonprofit worked with creative agency E/LA on the push.

Why pharma ads are on the bench during this year's Super Bowl

Why pharma ads are on the bench during this year's Super Bowl

For some pharma brands, the price tag is just too high. For others, the platform isn't serious enough.

Infographic | Docs, payers need pharma to step up

Infographic | Docs, payers need pharma to step up

For all the talk about new and better ways to engage, pharma still hasn't created an appreciably higher volume of satisfied — or informed — customers.

Infographic | HCPs must deal with communication breakdown

Infographic | HCPs must deal with communication breakdown

Drugmakers are proud of the patient service programs they've developed. Yet there remains a disconnect in the way information is communicated to HCPs.

Armed with predictive analytics, PBMs push adherence as a stand-in for outcomes

Armed with predictive analytics, PBMs push adherence as a stand-in for outcomes

Pharmacy benefit managers are increasingly measuring a patient's outcome in the context of adherence.

How Aubagio became the most switched-to oral MS drug

How Aubagio became the most switched-to oral MS drug

Second to market and dismissed as inferior to the competition, Sanofi's Aubagio seemed destined for lower-tier status. Here's how it overcame the initial obstacles and, five years later, become a potent market force

Why haven't biosimilars gained ground in the U.S.?

Why haven't biosimilars gained ground in the U.S.?

Two years after the first biosimilar approval in the U.S., biosimilars have yet to match sales forecasts. What is their path forward?

Merck to axe 1,800 sales positions, form new chronic-care sales team

Merck to axe 1,800 sales positions, form new chronic-care sales team

The drugmaker eliminated its U.S. primary care, disease-focused endocrinology, and hospital chronic-care sales teams.

Up to 20% of pharma brands moving digital media spend to point-of-care

Up to 20% of pharma brands moving digital media spend to point-of-care

Two point-of-care companies have received hundreds of millions of dollars in funding. One of them, Outcome Health, is facing allegations about padding data.

Drugmakers turn to social — not TV — to market drugs to women

Drugmakers turn to social — not TV — to market drugs to women

Still, most experts characterize this year's newly approved women's health drugs as modest improvements rather than groundbreaking advances in medicine.

Top 25 women's health brands, based on U.S. sales in 2016

Top 25 women's health brands, based on U.S. sales in 2016

Amgen's Prolia tops the list, according to data compiled by EvaluatePharma.

Infographic | The leaders of the global hepatitis-C market

Infographic | The leaders of the global hepatitis-C market

Despite approvals of competing products from AbbVie, Merck, and Bristol-Myers Squibb, Gilead remains the market leader.

Novartis' CAR-T therapy, now approved, faces questions about price and side effects

Novartis' CAR-T therapy, now approved, faces questions about price and side effects

The Swiss drugmaker is the first to receive FDA approval to market a CAR-T therapy.

Why Sanofi's dengue fever vaccine fell short of expectations

Why Sanofi's dengue fever vaccine fell short of expectations

Dengvaxia's post-launch plight reflects the difficulties of launching a vaccine. Is this a harbinger for future vaccine-marketing efforts?

Top 25 vaccine products in 2016, based on U.S. sales

Top 25 vaccine products in 2016, based on U.S. sales

Pfizer's Prevnar tops the list, according to data compiled by EvaluatePharma.

Investors put their money on point of care

Investors put their money on point of care

Two recent cash infusions suggest investors are bullish on point-of-care advertising. Is the channel ready for its moment in the spotlight?

Study: Hiking the prices of heart drugs led to fewer sales

Study: Hiking the prices of heart drugs led to fewer sales

Prescription rates dramatically decreased following the price hikes of Valeant's Isuprel and Nitropress in 47 hospitals.

Biogen, Merck use predictive modeling to better negotiate value-based contracts

Biogen, Merck use predictive modeling to better negotiate value-based contracts

What's holding back value-based pricing deals from moving beyond the pilot phase?

Point-of-care group rolls out guidelines

Point-of-care group rolls out guidelines

The goal is to further cement point of care as a mainstream media channel.

Top 25 oncology brands in 2016, based on U.S. sales

Top 25 oncology brands in 2016, based on U.S. sales

Celgene's Revlimid tops the list, according to data compiled by EvaluatePharma.

Pharma companies, now marketing high-science drugs, rely more on medical affairs

Pharma companies, now marketing high-science drugs, rely more on medical affairs

Five years ago, the notion of medical science liaisons as a guiding voice in the marketing mix was borderline preposterous. Now they're called upon early and often.

Cannabis nutrition company focuses on education

Cannabis nutrition company focuses on education

A particular focus is put on the emerging research about cannabis and its benefits for the human body.

Pharma spending on CME rose in 2016

Pharma spending on CME rose in 2016

It's the third year of consecutive growth for spending on accredited CME, according to the Accreditation Council for Continuing Medical Education.

For diabetes drugs, lowering blood sugar may no longer be enough to stay competitive

For diabetes drugs, lowering blood sugar may no longer be enough to stay competitive

Under siege from intense competition and the rise of value-based contracts, diabetes drugmakers look to outcomes data to stand out.

Outcome Health raises $500 million in financing round

Outcome Health raises $500 million in financing round

The deal highlights ongoing interest in the influential point-of-care market.

2017 Pharma Report: All the data in one place

2017 Pharma Report: All the data in one place

Find data on patent expirations, new drug approvals, top therapeutic classes, and top-selling drugs.

Pricing pressure is the new new normal for drugmakers

Pricing pressure is the new new normal for drugmakers

Drug prices, as you may have heard, are kind of high. But price growth has slowed after sharp spikes in 2014 and 2015.

Otsuka, Proteus refile their sensor-enabled drug

Otsuka, Proteus refile their sensor-enabled drug

The chip-in-a-pill combines antipsychotic Abilify with an ingestible sensor made by Proteus.

Back at Dendreon, Caggiano takes on Provenge's comeback

Back at Dendreon, Caggiano takes on Provenge's comeback

Jim Caggiano had witnessed Provenge's birth during an earlier turn at Dendreon and couldn't understand what went wrong.

Five things for pharma marketers to know: Monday, May 8, 2017

Five things for pharma marketers to know: Monday, May 8, 2017

Pfizer to provide Ibrance for free during NICE analysis; the FDA approves new ALS drug; people turn to Twitter to tell stories about pre-existing conditions

Value-based care requires innovators to challenge the status quo

Value-based care requires innovators to challenge the status quo

Execs stressed the importance of collaboration, consumer-mindedness.

4 reasons why patients don't fill their prescriptions

4 reasons why patients don't fill their prescriptions

Researchers still don't know why Americans who are prescribed a prescription drug to treat a chronic condition or disease so often fail to fill those prescriptions.

Drugmakers battle for slice of Humira's billions

Drugmakers battle for slice of Humira's billions

Makers of biosimilars have targeted a few of the top-selling autoimmune drugs. Get ready for some of the highest-stakes pricing and access skirmishes in recent pharma history.

Top 25 autoimmune brands in 2016, based on U.S. sales

Top 25 autoimmune brands in 2016, based on U.S. sales

AbbVie's Humira tops the list, according to data compiled by EvaluatePharma.

Study: Medical-marijuana laws lower prescription drug usage

Study: Medical-marijuana laws lower prescription drug usage

The research found a reduction in utilization of medications used to treat depression, nausea, and psychosis when looking at data for Medicaid beneficiaries.

5 of healthcare's hardest nuts to crack

5 of healthcare's hardest nuts to crack

How are pharma, clinical, and startup execs addressing some of the biggest challenges facing their businesses today?

How pharma marketers are using behavioral science

How pharma marketers are using behavioral science

A tool kit of pharma case studies and advice for healthcare brands in making behavioral science a foundational part of a marketing strategy.

Pro Ad Report: All the data on medical journal spending in 2016

Pro Ad Report: All the data on medical journal spending in 2016

The top three most advertised brands in 2016 were Gilead Sciences' Harvoni, Eli Lilly's Trulicity, and J&J's Invokana.

Top 25 respiratory brands, by sales

Top 25 respiratory brands, by sales

While still the top-selling respiratory drug, GSK's Advair is facing growing competition from BI's Spiriva and Roche's Xolair.

Drugmakers target severe asthma patients with biologics, but payers raise pricing issue

Drugmakers target severe asthma patients with biologics, but payers raise pricing issue

Biologics prompt asthma marketers to catch their collective breath as innovation has resulted in a rise of payer blockades and sky-high prices

Five things for pharma marketers to know: Wednesday, March 8, 2017

Five things for pharma marketers to know: Wednesday, March 8, 2017

Researchers question relationship between R&D costs and drug prices; Alexa uses WebMD to answer health questions; lawmakers push GAO to investigate orphan drugs

Some CME experts remain skeptical when it comes to social media

Some CME experts remain skeptical when it comes to social media

There are also issues surrounding privacy and legitimacy. According to one expert's research, very few physicians use social media for professional purposes.

Doctors seek more transparency from drugmakers: ePharma panel

Doctors seek more transparency from drugmakers: ePharma panel

Pharmaceutical companies often blur the lines between a drug's risks and benefits in ads, and that frustrates physicians.

Drugmakers again boost DTC spending, to $5.6 billion in 2016

Drugmakers again boost DTC spending, to $5.6 billion in 2016

Pfizer and Bristol-Myers Squibb were the top spenders last year.

2017 Healthcare Marketers Trend Report: All the data in one place

2017 Healthcare Marketers Trend Report: All the data in one place

The data stems from the 2017 MM&M/Guidemark Health Healthcare Marketers Trend Report.

Why Philips' Erik Hollander turned to reinvention

Why Philips' Erik Hollander turned to reinvention

He describes his current charge as "transforming a more creative occupation into a science."

Valeant beefs up Salix salesforce, to relaunch Addyi

Valeant beefs up Salix salesforce, to relaunch Addyi

Valeant added 250 primary care sales reps to promote its Salix portfolio.

Five things for pharma marketers to know: Tuesday, February 28, 2017

Five things for pharma marketers to know: Tuesday, February 28, 2017

J&J discloses list prices for its drugs; Kite's CAR-T therapy meets study goals; healthcare providers seek to engage patients in decisionmaking

Top 25 rare disease brands, by sales

Top 25 rare disease brands, by sales

Teva Pharmaceutical Industries' Copaxone is by far the top-selling drug, bringing in $3.2 billion in U.S. sales in 2015.

Orphan drugs face criticism on prices — and from patients

Orphan drugs face criticism on prices — and from patients

When discussing the nation's ability to stomach orphan drug costs, an analyst has called the price tag "the straw that breaks the camel's back."

On drug pricing, Acorda CEO is optimistic

On drug pricing, Acorda CEO is optimistic

Acorda CEO Ron Cohen applauded Marathon's move to pause the commercial activities for its new DMD drug.

Merck's DTC ad for Keytruda hints at more cancer brands turning to TV

Merck's DTC ad for Keytruda hints at more cancer brands turning to TV

Ads promoting Merck's and Bristol-Myers Squibb's immunotherapies could signal the beginning of a new era for DTC.

Allergan to boost investment in DTC for Kybella

Allergan to boost investment in DTC for Kybella

Allergan said it would increase its investment in DTC after reporting slowing sales for its double-chin injection.

GSK prepares for Advair competition

GSK prepares for Advair competition

If generic versions by Mylan, Hikma, and Vectura are approved mid-year, GSK expects sales of Advair to be flat or decline.

Gilead to use dating sites, Tumblr, and Snapchat in Truvada strategy

Gilead to use dating sites, Tumblr, and Snapchat in Truvada strategy

The drugmaker is planning a commercial boost for its HIV-prevention drug.

Three kinds of drugs, like those that treat RA and diabetes, drive increase in spending

Three kinds of drugs, like those that treat RA and diabetes, drive increase in spending

Spending for inflammatory drugs like AbbVie's Humira and Amgen's Enbrel rose, while hepatitis C drugs showed decline.

Sales of Keytruda miss analysts' mark

Sales of Keytruda miss analysts' mark

Thirty-percent of Keytruda's U.S. sales came from its lung-cancer indication.

WPP wins Walgreens account, to create 'Team WBA'

WPP wins Walgreens account, to create 'Team WBA'

WPP will create "Team WBA," a bespoke team that would work on traditional and digital advertising, media, and PR.

Five things for pharma marketers to know: Monday, January 30, 2017

Five things for pharma marketers to know: Monday, January 30, 2017

Merck details price increases for its drugs; Trump's call to freeze federal hiring may not affect the FDA; Sanofi to settle vaccines-pricing lawsuit

Merck and Aetna pair population health with risk-sharing in two deals

Merck and Aetna pair population health with risk-sharing in two deals

But have pharma and payers learned enough from earlier pilots to make modern risk-sharing deals work?

Infographic: How Trump will affect healthcare marketing budgets

Infographic: How Trump will affect healthcare marketing budgets

A new survey found that 34% of healthcare and pharma marketers say that the election of President Trump will not affect their marketing budgets.

Survey: 26% of brand execs say Trump will affect 2017 marketing budgets

Survey: 26% of brand execs say Trump will affect 2017 marketing budgets

A Haymarket Media survey of more than 700 client-side marcomms execs in the US reveals the shift in power will not significantly affect budgets.

Top 25 metabolic brands, by sales, 2015-2016

Top 25 metabolic brands, by sales, 2015-2016

Sanofi's Lantus is the top-selling product with its Lantus franchise. Merck's Januvia and Novo Nordisk's Victoza round out the top 3.

When it comes to diabetes, will marketers break with tradition?

When it comes to diabetes, will marketers break with tradition?

That may take a "focus on brand building that goes beyond 'ask your doctor if this drug is right for you.'"

If CSL Limited CEO Paul Perreault sneezes, Australia gets a cold

If CSL Limited CEO Paul Perreault sneezes, Australia gets a cold

"In Australia, we are the healthcare industry," he says.

Top 25 cardiovascular brands, 2015-2016

Top 25 cardiovascular brands, 2015-2016

The top-selling heart drug is Merck's Zetia, which is expected to bring in about $1.68 billion in sales in 2016.

When it comes to PCSK9s, payers resisted — and sales flopped

When it comes to PCSK9s, payers resisted — and sales flopped

The first two PCSK9s landed with a thud. What does their disappointing launch say about the need for marketers of CV drugs to get their pricing houses in order?

MM&M's top stories of 2016

MM&M's top stories of 2016

Find out what stories generated the most interest among our readers.

Five things for pharma marketers to know: Wednesday, December 7, 2016

Five things for pharma marketers to know: Wednesday, December 7, 2016

Trump puts pharma on notice over drug prices; Mylan lays off nearly 10% of its workforce; Pfizer slapped with U.K. antitrust fine

BI and Lilly face a new challenge: how to market a diabetes drug to cardiologists

BI and Lilly face a new challenge: how to market a diabetes drug to cardiologists

Boehringer Ingelheim and Eli Lilly have to position their third-in-class diabetes medication Jardiance as a heart drug.

Mylan CEO defends EpiPen strategy, questions pricing model in the U.S.

Mylan CEO defends EpiPen strategy, questions pricing model in the U.S.

Heather Bresch's appearance at industry summit came after she declined to attend a congressional hearing scheduled for the same day.

Five things for pharma marketers to know: Wednesday, November 30, 2016

Five things for pharma marketers to know: Wednesday, November 30, 2016

Astellas Pharma is searching for Xtandi successor; Novo Nordisk says Tresiba is safer than Lantus; Pfizer awards Nexium account to Grey

Two new therapies made by Sanofi and Novo Nordisk to compete in crowded diabetes market

Two new therapies made by Sanofi and Novo Nordisk to compete in crowded diabetes market

The FDA approved Sanofi's Soliqua and Novo Nordisk's Xultophy on Tuesday.

The doctor-patient dialogue: As productive as it's ever been or broken?

The doctor-patient dialogue: As productive as it's ever been or broken?

More barriers separate doctors and patients than ever before, from rising costs and time constraints to electronic health records and smartphones.

Evercore ISI's Umer Raffat on his predictions for pharma in 2017

Evercore ISI's Umer Raffat on his predictions for pharma in 2017

Specialty pharma ace Umer Raffat, a senior analyst at Evercore ISI, shares his 2016 postmortem and a few quick-hit predictions for 2017.

Kite Pharma to keep anticipated CAR-T launch 'controlled' and targeted at certain hospitals

Kite Pharma to keep anticipated CAR-T launch 'controlled' and targeted at certain hospitals

"This is not your grandfather's launch," said Shawn Tomasello, chief commercial officer of Kite Pharma.

Infographic: what information doctors need from pharma

Infographic: what information doctors need from pharma

How pharma distributes information to doctors is changing as rapidly as how doctors prefer to receive and process such information

With more marketing spend behind it, Eliquis gains on market leader Xarelto

With more marketing spend behind it, Eliquis gains on market leader Xarelto

BMS and Pfizer outspent Johnson & Johnson two-to-one in advertising for their oral anticoagulant last year.

Insurers seek to challenge millennial 'invincibility'

Insurers seek to challenge millennial 'invincibility'

Tech companies and Bernie Sanders have found the millennial audience easy to crack. Organizations in and around healthcare? Not so much.

Top 25 neurology products, based on 2016 sales forecasts

Top 25 neurology products, based on 2016 sales forecasts

MS drugs top the list, led by Teva's Copaxone, Biogen's Tecfida and Avonex, and Novartis' Gilenya.